Cargando…
Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...
Autores principales: | Clavreul, Anne, Roger, Emilie, Pourbaghi-Masouleh, Milad, Lemaire, Laurent, Tétaud, Clément, Menei, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225440/ https://www.ncbi.nlm.nih.gov/pubmed/30338715 http://dx.doi.org/10.1080/10717544.2018.1507061 |
Ejemplares similares
-
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
por: Clavreul, Anne, et al.
Publicado: (2019) -
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
por: Clavreul, Anne, et al.
Publicado: (2017) -
Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules
por: Clavreul, Anne, et al.
Publicado: (2015) -
Perfluorocarbon-Loaded Lipid Nanocapsules to Assess the Dependence of U87-Human Glioblastoma Tumor pO(2) on In Vitro Expansion Conditions
por: Lemaire, Laurent, et al.
Publicado: (2016) -
Amorphous calcium phosphate nanoparticles could function as a novel cancer therapeutic agent by employing a suitable targeted drug delivery platform
por: Pourbaghi-Masouleh, Milad, et al.
Publicado: (2013)